These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
311 related articles for article (PubMed ID: 19129318)
1. Cinacalcet use patterns and effect on laboratory values and other medications in a large dialysis organization, 2004 through 2006. St Peter WL; Li Q; Liu J; Persky M; Nieman K; Arko C; Block GA Clin J Am Soc Nephrol; 2009 Feb; 4(2):354-60. PubMed ID: 19129318 [TBL] [Abstract][Full Text] [Related]
2. Prescription patterns and mineral metabolism abnormalities in the cinacalcet era: results from the MBD-5D study. Fukagawa M; Fukuma S; Onishi Y; Yamaguchi T; Hasegawa T; Akizawa T; Kurokawa K; Fukuhara S Clin J Am Soc Nephrol; 2012 Sep; 7(9):1473-80. PubMed ID: 22822017 [TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Chonchol M; Locatelli F; Abboud HE; Charytan C; de Francisco AL; Jolly S; Kaplan M; Roger SD; Sarkar S; Albizem MB; Mix TC; Kubo Y; Block GA Am J Kidney Dis; 2009 Feb; 53(2):197-207. PubMed ID: 19110359 [TBL] [Abstract][Full Text] [Related]
4. Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Sprague SM; Evenepoel P; Curzi MP; González MT; Husserl FE; Kopyt N; Sterling LR; Mix C; Wong G Clin J Am Soc Nephrol; 2009 Sep; 4(9):1465-76. PubMed ID: 19696213 [TBL] [Abstract][Full Text] [Related]
5. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism. Dong BJ Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445 [TBL] [Abstract][Full Text] [Related]
6. The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Messa P; Macário F; Yaqoob M; Bouman K; Braun J; von Albertini B; Brink H; Maduell F; Graf H; Frazão JM; Bos WJ; Torregrosa V; Saha H; Reichel H; Wilkie M; Zani VJ; Molemans B; Carter D; Locatelli F Clin J Am Soc Nephrol; 2008 Jan; 3(1):36-45. PubMed ID: 18178780 [TBL] [Abstract][Full Text] [Related]
7. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690 [TBL] [Abstract][Full Text] [Related]
8. Economic analysis of cinacalcet in combination with low-dose vitamin D versus flexible-dose vitamin D in treating secondary hyperparathyroidism in hemodialysis patients. Shireman TI; Almehmi A; Wetmore JB; Lu J; Pregenzer M; Quarles LD Am J Kidney Dis; 2010 Dec; 56(6):1108-16. PubMed ID: 20951487 [TBL] [Abstract][Full Text] [Related]
9. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Block GA; Martin KJ; de Francisco AL; Turner SA; Avram MM; Suranyi MG; Hercz G; Cunningham J; Abu-Alfa AK; Messa P; Coyne DW; Locatelli F; Cohen RM; Evenepoel P; Moe SM; Fournier A; Braun J; McCary LC; Zani VJ; Olson KA; Drüeke TB; Goodman WG N Engl J Med; 2004 Apr; 350(15):1516-25. PubMed ID: 15071126 [TBL] [Abstract][Full Text] [Related]
10. Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients. Lee YT; Ng HY; Kuo CC; Chen TC; Wu CS; Chiu TT; Lee WC; Lee CT Nutrients; 2013 Apr; 5(4):1336-48. PubMed ID: 23603995 [TBL] [Abstract][Full Text] [Related]
11. Cinacalcet hydrochloride in chronic kidney disease-mineral bone disorder. Yokoyama K Clin J Am Soc Nephrol; 2009 Sep; 4(9):1405-8. PubMed ID: 19696214 [No Abstract] [Full Text] [Related]
12. Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Fishbane S; Shapiro WB; Corry DB; Vicks SL; Roppolo M; Rappaport K; Ling X; Goodman WG; Turner S; Charytan C Clin J Am Soc Nephrol; 2008 Nov; 3(6):1718-25. PubMed ID: 18945995 [TBL] [Abstract][Full Text] [Related]
13. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism. Bucharles SGE; Barreto FC; Riella MC J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274 [TBL] [Abstract][Full Text] [Related]
14. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. Lindberg JS; Culleton B; Wong G; Borah MF; Clark RV; Shapiro WB; Roger SD; Husserl FE; Klassen PS; Guo MD; Albizem MB; Coburn JW J Am Soc Nephrol; 2005 Mar; 16(3):800-7. PubMed ID: 15689407 [TBL] [Abstract][Full Text] [Related]
15. Combined therapy with cinacalcet and low doses of vitamin D sterols in patients with moderate to severe secondary hyperparathyroidism. Block GA; Zeig S; Sugihara J; Chertow GM; Chi EM; Turner SA; Bushinsky DA; Nephrol Dial Transplant; 2008 Jul; 23(7):2311-8. PubMed ID: 18310602 [TBL] [Abstract][Full Text] [Related]
16. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Charytan C; Coburn JW; Chonchol M; Herman J; Lien YH; Liu W; Klassen PS; McCary LC; Pichette V Am J Kidney Dis; 2005 Jul; 46(1):58-67. PubMed ID: 15983958 [TBL] [Abstract][Full Text] [Related]
17. [German observational trial on secondary hyperparathyroidism therapy with cinacalcet (EARLY)]. Reichel H; Braun J Dtsch Med Wochenschr; 2011 Jan; 136(4):123-8. PubMed ID: 21181622 [TBL] [Abstract][Full Text] [Related]
18. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease. Torres PU J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031 [TBL] [Abstract][Full Text] [Related]
19. The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. Quarles LD; Sherrard DJ; Adler S; Rosansky SJ; McCary LC; Liu W; Turner SA; Bushinsky DA J Am Soc Nephrol; 2003 Mar; 14(3):575-83. PubMed ID: 12595492 [TBL] [Abstract][Full Text] [Related]